Literature DB >> 10639424

Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis.

S L Leib1, D Leppert, J Clements, M G Täuber.   

Abstract

The present study was performed to evaluate the role of matrix metalloproteinases (MMP) in the pathogenesis of the inflammatory reaction and the development of neuronal injury in a rat model of bacterial meningitis. mRNA encoding specific MMPs (MMP-3, MMP-7, MMP-8, and MMP-9) and the inflammatory cytokine tumor necrosis factor alpha (TNF-alpha) were significantly (P < 0.04) upregulated, compared to the beta-actin housekeeping gene, in cortical homogenates at 20 h after infection. In parallel, concentrations of MMP-9 and TNF-alpha in cerebrospinal fluid (CSF) were significantly increased in rats with bacterial meningitis compared to uninfected animals (P = 0.002) and showed a close correlation (r = 0.76; P < 0. 001). Treatment with a hydroxamic acid-type MMP inhibitor (GM6001; 65 mg/kg intraperitoneally every 12 h) beginning at the time of infection significantly lowered the MMP-9 (P < 0.02) and TNF-alpha (P < 0.02) levels in CSF. Histopathology at 25.5 +/- 5.7 h after infection showed neuronal injury (median [range], 3.5% [0 to 17.5%] of the cortex), which was significantly (P < 0.01) reduced to 0% (0 to 10.8%) by GM6001. This is the first report to demonstrate that MMPs contribute to the development of neuronal injury in bacterial meningitis and that inhibition of MMPs may be an effective approach to prevent brain damage as a consequence of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10639424      PMCID: PMC97183          DOI: 10.1128/IAI.68.2.615-620.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid.

Authors:  S A Kolb; F Lahrtz; R Paul; D Leppert; D Nadal; H W Pfister; A Fontana
Journal:  J Neuroimmunol       Date:  1998-04-15       Impact factor: 3.478

2.  Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS.

Authors:  D C Anthony; K M Miller; S Fearn; M J Townsend; G Opdenakker; G M Wells; J M Clements; S Chandler; A J Gearing; V H Perry
Journal:  J Neuroimmunol       Date:  1998-07-01       Impact factor: 3.478

Review 3.  Matrix metalloproteinases and diseases of the CNS.

Authors:  V W Yong; C A Krekoski; P A Forsyth; R Bell; D R Edwards
Journal:  Trends Neurosci       Date:  1998-02       Impact factor: 13.837

4.  Matrix metalloproteinases in the cerebrospinal fluid of patients with Lyme neuroborreliosis.

Authors:  G Perides; M E Charness; L M Tanner; O Péter; N Satz; A C Steere; M S Klempner
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

5.  Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size.

Authors:  A M Romanic; R F White; A J Arleth; E H Ohlstein; F C Barone
Journal:  Stroke       Date:  1998-05       Impact factor: 7.914

6.  Alzheimer's amyloid precursor protein alpha-secretase is inhibited by hydroxamic acid-based zinc metalloprotease inhibitors: similarities to the angiotensin converting enzyme secretase.

Authors:  S Parvathy; I Hussain; E H Karran; A J Turner; N M Hooper
Journal:  Biochemistry       Date:  1998-02-10       Impact factor: 3.162

7.  Differential expression of matrix metalloproteinases in bacterial meningitis.

Authors:  B C Kieseier; R Paul; U Koedel; T Seifert; J M Clements; A J Gearing; H W Pfister; H P Hartung
Journal:  Brain       Date:  1999-08       Impact factor: 13.501

8.  Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states.

Authors:  A Pagenstecher; A K Stalder; C L Kincaid; S D Shapiro; I L Campbell
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

9.  Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke.

Authors:  D C Anthony; B Ferguson; M K Matyzak; K M Miller; M M Esiri; V H Perry
Journal:  Neuropathol Appl Neurobiol       Date:  1997-10       Impact factor: 8.090

10.  Gelatinase B modulates selective opening of the blood-brain barrier during inflammation.

Authors:  S Mun-Bryce; G A Rosenberg
Journal:  Am J Physiol       Date:  1998-05
View more
  71 in total

1.  Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis.

Authors:  Johann S Braun; Jack E Sublett; Dorette Freyer; Tim J Mitchell; John L Cleveland; Elaine I Tuomanen; Joerg R Weber
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 2.  Reprogramming the host response in bacterial meningitis: how best to improve outcome?

Authors:  M van der Flier; S P M Geelen; J L L Kimpen; I M Hoepelman; E I Tuomanen
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

3.  Use of corticosteroids and other adjunct therapies for acute bacterial meningitis in adults.

Authors:  Kameshwar Prasad; Nirendra Kumar Rai; Amit Kumar
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

4.  Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis.

Authors:  Denis Grandgirard; Melchior Burri; Philipp Agyeman; Stephen L Leib
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

5.  Persisting vasculitis after pneumococcal meningitis.

Authors:  Deborah Pugin; Jean-Christophe Copin; Marie-Christelle Goodyear; Theodor Landis; Yvan Gasche
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 6.  The paradox of matrix metalloproteinases in infectious disease.

Authors:  P T G Elkington; C M O'Kane; J S Friedland
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

7.  Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis.

Authors:  Damian N Meli; Roney S Coimbra; Dominik G Erhart; Gerard Loquet; Caroline L Bellac; Martin G Täuber; Ulf Neumann; Stephen L Leib
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

8.  Coadministration of branched-chain amino acids and lipopolysaccharide causes matrix metalloproteinase activation and blood-brain barrier breakdown.

Authors:  Giselli Scaini; Meline O S Morais; Leticia S Galant; Francieli Vuolo; Dhébora M Dall'Igna; Matheus A B Pasquali; Vitor M Ramos; Daniel P Gelain; Jose Claudio F Moreira; Patrícia F Schuck; Gustavo C Ferreira; Francisco G Soriano; Felipe Dal-Pizzol; Emilio L Streck
Journal:  Mol Neurobiol       Date:  2014-01-05       Impact factor: 5.590

Review 9.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

10.  Edaravone attenuates hippocampal damage in an infant mouse model of pneumococcal meningitis by reducing HMGB1 and iNOS expression via the Nrf2/HO-1 pathway.

Authors:  Zheng Li; Qian-Qian Ma; Yan Yan; Feng-Dan Xu; Xiao-Ying Zhang; Wei-Qin Zhou; Zhi-Chun Feng
Journal:  Acta Pharmacol Sin       Date:  2016-08-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.